financetom
Business
financetom
/
Business
/
Famous Footwear Parent Caleres Suspends Outlook On China Risk, Stock Plunges
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Famous Footwear Parent Caleres Suspends Outlook On China Risk, Stock Plunges
May 29, 2025 8:00 AM

Caleres, Inc. ( CAL ) shares are trading lower after the company reported first-quarter FY25 results.

Revenues fell 6.8% year over year (Y/Y) to $614.2 million, missing the analyst consensus of $622.05 million.

Famous Footwear sales fell 6.3% Y/Y, with comparable store sales down 4.6% Y/Y. Brand Portfolio sales decreased 6.9% Y/Y in the quarter.

Also Read: Costco Wholesale Q3 Earnings Preview: Will Company Discuss Price Increases After Prior Trump Team Backlash?

The company’s gross margin rate contracted 150 basis points year over year to 45.4% and adjusted EBITDA fell to $28.7 million from $57.4 million a year ago quarter.

The adjusted EPS of 22 cents missed the consensus of 36 cents.

Jay Schmidt, president and CEO, said, “While our brands continue to resonate with consumers and both segments of our business gained market share in the period, our first quarter results fell short of expectations.”

“February sales were particularly weak, and although trends improved in March and April, overall performance was below plan. Furthermore, operating earnings were pressured by lower gross margins, increased reserves, and costs to cancel and move inventory.”

“In the near term, we are focused on controlling what we can control, including optimizing our sourcing strategy. Additionally, we expect to decrease SG&A by $15 million on an annualized basis through structural expense cuts,” he added.

In the quarter, Caleres ( CAL ) returned 300,000 shares to shareholders at an average price of $16.81 per share.

Borrowings under the revolving credit facility totaled $258.5 million at the end of the period, up $67.5 million from the first quarter of 2024.

Caleres ( CAL ) said it currently expects dollars sourced from China to be 10% or less by the second half of 2025.

Given the uncertainty in the environment, the company suspended guidance for the fiscal 2025 outlook.

During the fourth-quarter FY24 earnings call, the company guided FY25 net sales to decline by 1% to up 1%, with an EPS of $2.80 – $3.20.

Price Action: CAL shares are trading lower by 14.5% to $14.01 at last check Thursday.

Read Next:

Abercrombie Is Hot Again — Here’s Why Your Retail ETF Didn’t Get The Memo

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
TransAlta Down in U.S. Pre-market trading After Booking Q3 Loss
TransAlta Down in U.S. Pre-market trading After Booking Q3 Loss
Nov 6, 2025
07:30 AM EST, 11/06/2025 (MT Newswires) -- TransAlta's ( TAC ) share price fell 2.7% at last look Thursday in New York Stock Exchange trading as the company swung to an adjusted net loss widened in the third quarter. TransAlta ( TAC ) posted an adjusted net loss of C$8 million, or a loss of $0.02 per share, reversing the...
Quantum computing systems firm D-Wave's Q3 revenue beats
Quantum computing systems firm D-Wave's Q3 revenue beats
Nov 6, 2025
Overview * D-Wave fiscal Q3 revenue grows 100% yr/yr, beating analyst expectations * Company reports highest cash balance in history at $836 mln * Net loss for fiscal Q3 increases due to non-cash warrant liability charges Outlook * Company did not provide specific financial guidance for future periods Result Drivers * REVENUE GROWTH - Co reports 100% yr/yr revenue increase...
US FDA expands use of J&J's Caplyta as add-on depression drug
US FDA expands use of J&J's Caplyta as add-on depression drug
Nov 6, 2025
Nov 6 (Reuters) - The U.S. Food and Drug Administration has approved the expanded use of Johnson & Johnson's ( JNJ ) drug Caplyta as an add-on treatment for adults with major depressive disorder, the company said on Thursday. J&J gained access to Caplyta with its $14.6 billion acquisition of neurological drugmaker Intra-Cellular Therapies in January. The FDA's decision marks...
Healthcare tech firm CareCloud's Q3 revenue up 9%, beats expectations
Healthcare tech firm CareCloud's Q3 revenue up 9%, beats expectations
Nov 6, 2025
Overview * CareCloud ( CCLD ) Q3 revenue rises 9% yr/yr, beating analyst expectations * Company raises full-year 2025 revenue guidance to $117-$119 mln * CareCloud ( CCLD ) completes Medsphere acquisition, accelerates AI initiatives Outlook * CareCloud ( CCLD ) raises full-year 2025 revenue guidance to $117-$119 mln * Company expects full-year 2025 adjusted EBITDA of $26-$28 mln *...
Copyright 2023-2026 - www.financetom.com All Rights Reserved